Business context and reporting period
Filing identity mismatch: The supplied filing is StemCells, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2015—not a filing by Microbot Medical Inc. The summary below reflects the filing as provided.
StemCells was a biopharmaceutical company developing cell-based therapeutics. Its HuCNS-SC programs included clinical studies for chronic spinal cord injury and dry age-related macular degeneration (AMD). In late 2014, it sold its SC Proven reagent and cell-culture business and wound down its UK subsidiary operations, reporting those activities as discontinued operations.
Key financial metrics
| Metric | Q1 2015 | Q1 2014 / comparison |
|---|---|---|
| Revenue | $21,000 | $24,000; down 11% |
| Operating expenses | $8.98 million | $6.87 million; up 31% |
| Research and development | $6.29 million | $4.63 million; up 36% |
| General and administrative | $2.69 million | $2.24 million; up 20% |
| Operating loss | $8.96 million | $6.84 million |
| Net loss | $9.35 million | $7.62 million |
| Basic and diluted loss per share | $0.14 | $0.14 |
| Operating cash used | $8.91 million | $6.51 million |
| Cash and cash equivalents at quarter end | $14.15 million | $24.99 million at Dec. 31, 2014 |
Revenue was entirely from licensing agreements; product sales in the reported quarter were zero. Gross margin is not meaningfully presented for continuing operations given the very limited licensing revenue and absence of reported product sales. Q1 comprehensive loss was $9.38 million.
Liquidity, debt and material changes
Cash declined by $10.84 million from year-end. Total liabilities were $23.60 million, exceeding total assets of $21.25 million; stockholders’ equity was negative $2.35 million. Loan payable, net of discount, totaled $13.37 million, including $4.10 million current and $9.27 million non-current. The company repaid about $1.68 million of loan principal during the quarter.
Operating cash use increased 37% year over year, driven mainly by the larger net loss and operating cash-flow timing. R&D expense rose primarily due to personnel and stock-based compensation, Phase II spinal-cord-injury trial costs, preclinical services, and manufacturing/process-development work. G&A growth was primarily attributable to payroll and stock-based compensation. Other expense narrowed to $390,000 from $720,000, partly because interest expense fell; the 2015 period also included a gain associated with the Rhode Island property sale.
In April 2015, after quarter-end, StemCells reported raising approximately $25 million gross in a public offering of 35.715 million units, each comprising one common share and a warrant for 0.75 share at $0.85 per share. The underwriters also exercised an over-allotment option for warrants to purchase approximately 4.018 million shares. The filing states 105,097,782 common shares issued and outstanding at April 30, 2015, versus 69,311,545 at March 31; the offering therefore materially increased potential and actual dilution. This post-quarter financing is not reflected in March 31 cash or the quarter’s financial statements.
Outlook, commentary, risks and unusual items
- Management expected substantial future operating losses and said the company needed significant additional capital. It warned that if financing were unavailable, it could have to delay, reduce or eliminate development programs and might be unable to meet obligations; the filing also notes possible bankruptcy proceedings if cash were exhausted without adequate financing.
- The April offering provided additional gross proceeds, but the company remained dependent on external financing and clinical, regulatory and commercial outcomes. It did not provide specific revenue, profit or commercialization guidance.
- Management reported that the first six-patient cohort of the Phase II spinal cord injury study was completed in April. The study planned up to 52 participants; a subsequent 40-patient cohort was intended to assess efficacy. The filing also described positive interim observations in earlier spinal cord injury and AMD studies, which are preliminary and do not establish efficacy.
- The Alzheimer’s preclinical program was wound down after it did not meet CIRM’s continuation criteria. StemCells repaid approximately $679,000 of CIRM funding; approximately $8.92 million principal and $243,000 accrued interest were described as forgiven, but the liability had not been derecognized pending required conditions, including legal release.
- Warrant liability was $2.03 million at quarter-end, up $347,000 during the quarter; the fair-value change was recorded as an expense and relied in part on subjective valuation assumptions. The company also disclosed a long-running patent dispute with Neuralstem, including a pending court ruling on StemCells’ standing to pursue its claims.
- Contractual obligations totaled approximately $20.44 million, including $15.73 million of operating lease payments and $4.68 million of loan principal and interest. Management stated no material change to the risk factors in its 2014 Form 10-K. Disclosure controls were assessed as effective, with no material quarterly change in internal controls reported.
Important facts for investors to verify
- Confirm the issuer: the filing identifies StemCells, Inc., not Microbot Medical Inc.
- Review the April 2015 offering’s net proceeds, final securities issued, warrant terms and resulting fully diluted share count; distinguish post-quarter financing from March 31 liquidity.
- Assess cash runway against the reported $8.91 million quarterly operating cash use, debt repayments, lease commitments and planned clinical-trial spending.
- Verify the legal status and accounting treatment of the CIRM loan forgiveness, and monitor the Neuralstem litigation and warrant-liability valuation.
- Evaluate clinical progress and regulatory requirements independently; the filing’s interim study results are preliminary and the company reported no meaningful timetable for commercialization or profitability.